Mostrar el registro sencillo

dc.contributor.authorGonzález-Lamuño Leguina, Domingo 
dc.contributor.authorArrieta-Blanco, Francisco Jesús
dc.contributor.authorDios Fuentes, Elena
dc.contributor.authorForga-Visa, María Teresa
dc.contributor.authorMorales-Conejo, Monstserrat
dc.contributor.authorLuis Peña-Quintana
dc.contributor.authorVitoria-Miñana, Isidro
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2024-02-29T17:15:55Z
dc.date.available2024-02-29T17:15:55Z
dc.date.issued2024
dc.identifier.issn2072-6643
dc.identifier.urihttps://hdl.handle.net/10902/32002
dc.description.abstractHyperhomocysteinemia (HHcy) is recognized as an independent risk factor for various significant medical conditions, yet controversy persists around its assessment and management. The diagnosis of disorders afffecting homocysteine (Hcy) metabolism faces delays due to insufficient awareness of its clinical presentation and unique biochemical characteristics. In cases of arterial or venous thrombotic vascular events, particularly with other comorbidities, it is crucial to consider moderate to severe HHcy. A nutritional approach to HHcy management involves implementing dietary strategies and targeted supplementation, emphasizing key nutrients like vitamin B6, B12, and folate that are crucial for Hcy conversion. Adequate intake of these vitamins, along with betaine supplementation, supports Hcy remethylation. Lifestyle modifications, such as smoking cessation and regular physical activity, complement the nutritional approach to enhance Hcy metabolism. For individuals with HHcy, maintaining a plasma Hcy concentration below 50 µmol/L consistently is vital to lowering the risk of vascular events. Collaboration with healthcare professionals and dietitians is essential for developing personalized dietary plans addressing the specific needs and underlying health conditions. This integrated approach aims to optimize metabolic processes and reduce the associated health risks.es_ES
dc.description.sponsorshipAECOM The Spanish Society for the Study of Inborn Errors of Metabolism collaborated in the publication and promotion of the article. Recordati Rare Diseases collaborates with AECOM to promote the identification of HCU patients and supports meetings and actions in education of professionals.es_ES
dc.format.extent14 p.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rights© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) licensees_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceNutrients, 2024, 16, 135es_ES
dc.subject.otherHomocysteinees_ES
dc.subject.otherHyperhomocysteinemiaes_ES
dc.subject.otherHomocystinuriaes_ES
dc.subject.otherInborn metabolic diseaseses_ES
dc.subject.otherTranssulfurationes_ES
dc.subject.otherRemethylationes_ES
dc.subject.otherThrombotic eventses_ES
dc.subject.otherMarfanoid habituses_ES
dc.subject.otherEctopia lentises_ES
dc.subject.otherBetainees_ES
dc.titleHyperhomocysteinemia in adult patients: a treatable metabolic conditiones_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersion10.3390/nu16010135es_ES
dc.rights.accessRightsopenAccesses_ES
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) licenseExcepto si se señala otra cosa, la licencia del ítem se describe como © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license